Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Man Group plc Grows Holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
10:34am, Monday, 06'th Apr 2020
Man Group plc increased its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 8.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The ins
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Stock Holdings Reduced by Baird Financial Group Inc.
08:46am, Monday, 06'th Apr 2020
Baird Financial Group Inc. cut its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 7.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange
UBS says stick to these strong-balance-sheet stocks that can withstand shocks
04:09pm, Sunday, 05'th Apr 2020
"Balance sheet strength is critical right now as companies may suffer significant revenue disruption ahead," UBS analyst Paul Winter said in a note to clients.
Marshall Wace LLP Purchases 455 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
11:12am, Sunday, 05'th Apr 2020
Marshall Wace LLP lifted its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 81.1% during the fourth quarter, according to the company in its most recent disclosure with the Securitie
Janus Henderson Group PLC Sells 380,819 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
10:04am, Sunday, 05'th Apr 2020
Janus Henderson Group PLC lessened its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 65.4% during the fourth quarter, according to the company in its most recent filing with the Securities &
Geode Capital Management LLC Grows Holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
10:54am, Saturday, 04'th Apr 2020
Geode Capital Management LLC raised its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Expected to Announce Quarterly Sales of $169.97 Million
09:00am, Saturday, 04'th Apr 2020
Equities research analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post $169.97 million in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Ionis Phar
SVB Leerink Weighs in on Ionis Pharmaceuticals Inc's Q1 2020 Earnings (NASDAQ:IONS)
06:00am, Saturday, 04'th Apr 2020
Ionis Pharmaceuticals Inc (NASDAQ:IONS) – SVB Leerink lowered their Q1 2020 earnings estimates for shares of Ionis Pharmaceuticals in a report issued on Tuesday, March 31st. SVB Leerink analyst M. F
Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic
12:33am, Saturday, 04'th Apr 2020
Last month French biotech Dynacure dosed the first patient in an early-stage trial of its lead drug candidate, a treatment for a group of rare genetic
Analysts' Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Minerva Neurosciences (NERV) and
Analysts’ Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (
SGEN
–
Research Report
), Minerva Neurosciences (
NERV
–
Research Report
) and O
Vericel (VCEL) Gets a Hold Rating from Needham
07:01pm, Thursday, 02'nd Apr 2020
In a report released today, Chad Messer from Needham maintained a Hold rating on Vericel (VCEL). The company's shares closed last Thursday at $8.48, close
Vericel (VCEL) Gets a Hold Rating from Needham
07:01pm, Thursday, 02'nd Apr 2020
In a report released today,
Chad Messer
from Needham maintained a
Hold
rating on Vericel (
VCEL
–
Research Report
). The company’s shares closed last Thursday at $8.48, close to its 52-week low of
Needham Keeps Their Buy Rating on Seattle Genetics (SGEN)
06:51pm, Thursday, 02'nd Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Seattle Genetics (SGEN) today and set a price target of $144.00. The company's shares closed last
Needham Keeps Their Buy Rating on Seattle Genetics (SGEN)
06:51pm, Thursday, 02'nd Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Seattle Genetics (SGEN – Research Report) today and set a price
